META-AF Trial – Metformin Reduces Arrhythmia Recurrence After AF Ablation in Overweight, Non-diabetic Patients
Key Points: Obesity is a well-established risk factor for atrial fibrillation (AF) and is associated with greater risk of AF progression and treatment failure. Observational... Read more.
ABC-AF Trial: Personalized Risk-Based Treatment Did Not Improve Outcomes in Patients with Atrial Fibrillation
Key Points: The ABC-AF trial evaluated whether treatment recommendations based on biomarker-based risk scores could improve outcomes compared with standard guideline-based... Read more.
BaxHTN: Baxdrostat Significantly Reduced Blood Pressure in Patients with Uncontrolled or Resistant Hypertension
Key Points: Uncontrolled and resistant hypertension remains a major challenge despite treatment with multiple antihypertensive agents. Baxdrostat, a selective aldosterone... Read more.
HI-PRO Trial: Extended Low-Intensity Apixaban Reduces Recurrent VTE in Patients with Provoked VTE and Enduring Risk Factors
Key Points: Standard anticoagulation for provoked venous thromboembolism (VTE) is often discontinued after 3–6 months, but patients with enduring risk factors... Read more.
MAPLE-HCM: Aficamten Superior to Metoprolol for Improving Exercise Capacity in Symptomatic Obstructive HCM
Key Points: Beta-blockers are widely used as first-line therapy for obstructive hypertrophic cardiomyopathy (HCM), despite limited evidence supporting their efficacy.... Read more.
LOSE-AF: Weight Loss Alone Does Not Improve AF Symptoms or Burden in Older Adults
Key Points: LOSE-AF is the first randomized trial to rigorously assess the effect of structured weight loss on AF symptoms in older adults with persistent atrial... Read more.
PRAGUE-25: Lifestyle Modification Plus Antiarrhythmic Drugs Inferior to Catheter Ablation In Obese Patients
Key Points: Obesity increases the risk of atrial fibrillation (AF) by 19–29% for every 5-unit increase in BMI. While catheter ablation has been more effective... Read more.
ZENITH Trial: Sotatercept Significantly Reduces Major Morbidity and Mortality Events in High-Risk PAH Patients
Key Points: Pulmonary arterial hypertension (PAH) is a progressive disease with poor outcomes despite advancements in therapy. Sotatercept, a novel activin signaling... Read more.
Evolut Low Risk Trial: TAVR Non-inferior to Surgical AR at 5 Years in Low-Risk Patient With Severe AS
Key Points: In the initial Evolut Low Risk Trial, patients with severe aortic stenosis who were at low surgical risk had noninferior outcomes with TAVR using a self-expanding... Read more.
FAIR-HF2 Trial: IV Iron Improves Quality of Life But Not CV Events in Heart Failure
Key Points: Iron deficiency is common in patients with heart failure with reduced ejection fraction (HFrEF) and is associated with worse outcomes. The FAIR-HF2 trial... Read more.